SS18 and synovial sarcoma: Although the majority of synovial sarcomas do not seem to profit from cancer vaccines targeting the SS18-SSX gene fusion, many other neoantigens derived from gene fusions that drive the oncogenesis in sarcoma types have not yet been included in clinical trials.